These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30641166)

  • 41. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
    Buse JB; Han J; Miller S; MacConell L; Pencek R; Wintle M
    Curr Med Res Opin; 2014 Jul; 30(7):1209-18. PubMed ID: 24621255
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
    Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
    Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
    Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patients.
    Siegmund T; Pfohl M; Forst T; Pscherer S; Bramlage P; Foersch J; Borck A; Seufert J
    Diabetes Metab Syndr; 2017; 11(1):51-57. PubMed ID: 27578616
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study).
    Odawara M; Matsuhisa M; Hirose T; Koshida R; Senda M; Tanaka Y; Terauchi Y
    Expert Opin Pharmacother; 2020 Oct; 21(14):1771-1780. PubMed ID: 32693663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
    Russel-Szymczyk M; Valov V; Savova A; Manova M
    BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries.
    van Mark G; Lanzinger S; Sziegoleit S; Putz FJ; Durmaz M; Borscheller M; Danne T; Seufert J; Holl RW; Bramlage P
    Adv Ther; 2019 Jul; 36(7):1628-1641. PubMed ID: 31119688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study.
    Taki K; Koyanagi M; Nagaoka S; Shingaki T
    Curr Med Res Opin; 2020 Dec; 36(12):1975-1983. PubMed ID: 33030354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
    Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
    Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
    Escalada J; Bonnet F; Wu J; Bonnemaire M; Gupta S; Cambron-Mellott JM; Nicholls C; Müller-Wieland D
    Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
    Meneghini L; Doshi A; Gouet D; Vilsbøll T; Begtrup K; Őrsy P; Ranthe MF; Lingvay I
    Diabet Med; 2020 Feb; 37(2):267-276. PubMed ID: 31705547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes.
    Tibaldi J; Hadley-Brown M; Liebl A; Haldrup S; Sandberg V; Wolden ML; Rodbard HW
    Diabetes Obes Metab; 2019 Apr; 21(4):1001-1009. PubMed ID: 30552800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: Adriatic countries data meta-analysis.
    Cigrovski Berkovic M; Petrovski G; Grulovic N
    Acta Diabetol; 2016 Oct; 53(5):709-15. PubMed ID: 27098531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: a randomized noninferiority trial.
    Harris SB; Yale JF; Berard L; Stewart J; Abbaszadeh B; Webster-Bogaert S; Gerstein HC
    Diabetes Care; 2014; 37(3):604-10. PubMed ID: 24170757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative effectiveness and safety of different basal insulins in a real-world setting.
    Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
    Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of weight-based insulin glargine dose titration regimen compared with glucose level- and current dose-based regimens in hospitalized patients with type 2 diabetes: a randomized, controlled study.
    Li X; Du T; Li W; Zhang T; Liu H; Xiong Y
    Clin Ther; 2014 Sep; 36(9):1269-75. PubMed ID: 25062651
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Titration of Insulin Glargine in Patients with Type 2 Diabetes Mellitus in Asia: Physician- Versus Patient-Led? Rationale of the Asian Treat to Target Lantus Study (ATLAS).
    ATLAS Study Group
    Diabetes Technol Ther; 2011 Jan; 13(1):67-72. PubMed ID: 21175274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.